Marvel Biosciences Corp (MRVL : TSX-V)
Common Stock
$0.15
CAD
+0.00 (%)
Last updated: 2026-09-03
Get MRVL alerts:
MRVL
Marvel Biosciences Corp
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
-14.29%
YTD
+11.11%
Key Statistics
Market Cap
$9.45M
52W High
$0.28
52W Low
$0.12
P/E Ratio
-
50 Day MA
$0.16
200 Day MA
$0.16
Beta
0.58
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/3/2026 | $0.15 | $0.15 | $0.14 | $0.15 | $0.15 | 43,596 |
| 9/2/2026 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 17,001 |
| 9/1/2026 | $0.15 | $0.15 | $0.14 | $0.15 | $0.15 | 36,014 |
| 8/31/2026 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 12,637 |
| 8/28/2026 | $0.15 | $0.15 | $0.14 | $0.15 | $0.15 | 78,426 |
| 8/27/2026 | $0.15 | $0.15 | $0.14 | $0.15 | $0.15 | 71,600 |
| 8/26/2026 | $0.14 | $0.15 | $0.14 | $0.15 | $0.15 | 70,333 |
| 8/25/2026 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 23,927 |
| 8/24/2026 | $0.16 | $0.16 | $0.15 | $0.15 | $0.15 | 18,610 |
| 8/21/2026 | $0.17 | $0.17 | $0.15 | $0.15 | $0.15 | 18,112 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRVL's historical volatility
30-Day Vol
79.1%
Annualized
90-Day Vol
129.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.14 | C$0.11 – C$0.19 |
| 60 trading days | C$0.13 | C$0.09 – C$0.20 |
| 90 trading days | C$0.13 | C$0.08 – C$0.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.19M
- Profit Margin
- 0.00%
- ROE (TTM)
- -380.30%
- EPS (Diluted)
- -0.03
- Book Value
- -0.04
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About MRVL
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
MRVL.V news timeline
5 articles covering MRVL.V, most recent first
Latest